Why the study?
Does ICI 141.292 improve exercise duration and hemodynamic parameters in patients with severe angina pectoris?
Does ICI 141.292 improve exercise duration and hemodynamic parameters in patients with severe angina pectoris?
ICI 141.292 at doses of 200 and 300 mg daily effectively reduces maximal heart rate and blood pressure while increasing exercise duration in patients with severe angina pectoris.
Answers are grounded in this paper and cite their sources.
200-300 mg ICI 141.292 improves exercise capacity in severe angina; confirms dose-dependent beta-blockade efficacy in RCT.
In a placebo-controlled, randomized double-blind study the effect of ICI 141.292 (beta 1-selective beta-blocker with intrinsic sympathomimetic activity = ISA) was studied in 11 patients with severe angina pectoris. The doses used were 100, 200 and 300 mg once daily. The 24-hour heart rate was significantly reduced by all regimens, and the Holter-monitoring pattern indicated the presence of ISA-effect at least 20 hours after the 300-mg dose. Maximal heart rate and blood pressure were significantly reduced and exercise duration increased during a symptom-limited bicycle exercise test on 200 and 300 mg, but not on 100 mg daily. Resting heart rate and blood pressure were uninfluenced on all regimens. ICI 141.292 is an effective agent in patients with severe angina pectoris. The response pattern suggests the presence of clinically relevant ISA.
No takes yet. Share an insight, caveat, or question.
Erikssen et al. (1988) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: